The story
On 1 April 2025, Czechia widened the front door to its medical-cannabis programme. General practitioners joined the specialists who could prescribe, though their new authority was confined to one indication: chronic intractable pain.
Beyond specialist clinics
The original 2013 medical system tied prescribing to specified specialist qualifications. SÚKL’s 2025 clinical guidance lists fields including oncology, neurology, palliative medicine, pain medicine, rheumatology, orthopaedics, infectious medicine, internal medicine, ophthalmology, dermatology, geriatrics and psychiatry.
The 2025 change added general medicine. It did not give GPs an unrestricted cannabis prescription power: SÚKL says they may prescribe it for chronic intractable pain, diagnosis R52.1. The guidance identifies cancer-related, degenerative musculoskeletal, connective-tissue, neuropathic and glaucoma pain among the conditions that can fall within that category.
Longer prescriptions
The same framework allowed one prescription to cover as much as three months of treatment. That reduced the need for monthly prescription renewals, but it did not multiply the quantity allowed each month.
SÚKL states that the overall ceiling remains 180 grams of dried cannabis a month, with extracts converted for the calculation at one gram of extract to three grams of flower. Public insurance ordinarily covers 90% of the final price for up to 30 grams a month; a higher reimbursed quantity requires the insurer’s approval based on the prescriber’s justification.
A controlled pharmacy system
Medical cannabis remained a pharmacy medicine. Prescriptions are electronic and marked for a highly addictive substance. They identify flower or extract, THC and CBD content, route of administration, dosage and total quantity. Pharmacists check the restricted-medicines register before preparing or dispensing it.
The reform therefore broadened who could initiate treatment for a common indication without turning medical cannabis into an over-the-counter product. It addressed access to a prescriber, not the rules for recreational possession, home growing or supply.
What moved in the index
Nothing moved in the Cannabis Freedom Index. The access segment had already risen when prescription cannabis was legalised, and expanding the pool of eligible doctors did not create a new access tier. It is nevertheless a national implementation milestone in the medical system described on the Czechia profile.[1][2]
Listed for context. No score change is recorded for Czechia here.
References
Checked. The date and the event were compared with a source that was read.